

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed's Brinsupri nabs landmark FDA nod in chronic lung disease
Details : Brinsupri (brensocatib) is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
Product Name : Brinsupri
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2025
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $750.0 million
Deal Type : Public Offering
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
Details : Insmed intends to use the net proceeds to fund continued research and development of INS1007 (brensocatib), for non-cystic fibrosis bronchiectasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 11, 2025
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $750.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Won’t Hold Advisory Meeting to Discuss NDA for Brensocatib
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ASPEN Study Subgroup Shows Consistency in Brensocatib’s Efficacy in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $650.0 million
Deal Type : Public Offering
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Details : Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $650.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $500.0 million
Deal Type : Public Offering
Insmed Announces Proposed $500 Million Public Offering of Common Stock
Details : The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $500.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed Announces Positive Results from ASPEN Study of Brensocatib in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brensocatib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brensocatib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : Brensocatib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
